Objective:

To advance SeaBeLife's dual-pathway strategy targeting retinal degeneration by appointing Professor Eric Souied to its scientific committee, which focuses on innovative treatment mechanisms.

Approach:

Key Findings:

• Souied has extensive expertise in AMD, having authored over 650 scientific publications.
• He identified the first genetic polymorphism associated with AMD in 1998.
• SeaBeLife's lead candidate, SBL03, has shown preclinical efficacy in geographic atrophy (GA), which is projected to affect 10 million people by 2040.

Interpretation:

Souied's appointment strengthens SeaBeLife's scientific foundation and enhances its focus on innovative treatment strategies for retinal degeneration.

Limitations:

• Limited treatment options for GA in Europe highlight the urgent need for effective therapies as cases are projected to rise significantly.

Conclusion:

The collaboration aims to develop a disease-modifying approach to retinal degeneration, focusing on innovative strategies that target underlying mechanisms rather than just alleviating symptoms.

Sources:

• Andrew Lloyd & Associates
Source

Based on findings from:

Eric Souied Joins SeaBeLife

The Ophthalmologist, 2026.

https://www.theophthalmologist.com/issues/2026/articles/march/eric-souied-joins-seabelife/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.